COVID-19 vaccination status and associated factors among lactating women during the COVID-19 outbreak: a cross-sectional study in southern China

Xiaofen Wang 1, Kun Tang 2, Rong Huang 3, Simin Yi 4

ABSTRACT

Objectives Different countries and institutions around the world have debated whether lactating women should receive the COVID-19 vaccine during the COVID-19 pandemic. In China, lactating is not a contraindication to vaccination, but many women are still hesitant to get vaccinated. The purpose of this study was to investigate the current status of COVID-19 vaccination among lactating women and the related factors affecting vaccination.

Methods An online cross-sectional survey involving 506 lactating women was conducted in southern China. We explored the related factors affecting COVID-19 vaccination of lactating women from three aspects: general information, knowledge–attitude–behaviour towards COVID-19 and its vaccine, and postpartum psychological state.

Results A total of 432 lactating women completed the questionnaire, 198 of whom had received the COVID-19 vaccine. On the knowledge–attitude–behaviour questionnaire on COVID-19 and its vaccines, the vaccinated group scored higher than the unvaccinated group on both the three subdimensions of the questionnaire and the total score (p<0.01). The results of binary logistics regression analysis showed that mixed feeding (OR=2.68, 95% CI: 1.82 to 3.96), longer breastfeeding duration (OR=1.31, 95% CI: 1.16 to 1.49), better physical condition (OR=5.28, 95% CI: 1.82 to 15.32), higher attitude score of COVID-19 and its vaccine (OR=1.18, 95% CI: 1.10 to 1.27), and having a travel history in medium high-risk areas (OR=3.49, 95% CI: 1.46 to 8.37) were significantly associated with COVID-19 vaccination in lactating women. Having a master’s degree or above (OR=0.03, 95% CI: 0.01 to 0.30), and having higher anxiety score (OR=0.66, 95% CI: 0.54 to 0.81) and depression score (OR=0.84, 95% CI: 0.75 to 0.93) were inversely associated with COVID-19 vaccination in lactating women.

Conclusion 45.8% of lactating women were vaccinated against COVID-19. Education level, feeding methods, duration of breast feeding, travel history in medium high-risk areas, physical condition, attitude score of COVID-19 and its vaccine, anxiety symptom and depressive symptom score were associated with vaccination of lactating women. More interventions based on these factors were needed to reduce concerns for lactating women and increase their vaccination rates.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This study explores the status and related factors of vaccination against COVID-19 among lactating women during the COVID-19 outbreak in a setting where there are limited data.

⇒ A self-developed and pre-validated knowledge–attitude–behaviour questionnaire was used to investigate the cognition and performance of lactating women on COVID-19 and its vaccine.

⇒ The willingness of lactating women to be vaccinated is time limited and may be influenced by the high prevalence and mortality rates of the current outbreak.

⇒ This is a cross-sectional study and causality could not be inferred.

⇒ There are other possible biases such as sampling bias due to lower responses in lactating women with limited internet access, social desirability bias in responses and recall bias in responses.

INTRODUCTION

The global pandemic of COVID-19 has brought a huge disease burden and high mortality to all countries. According to the WHO, the virus has caused more than 6 million deaths from the pandemic so far. 1, 2 Therefore, countries around the world are intensively carrying out research on COVID-19 and its vaccines to reduce the risk of contracting this disease. As the ongoing available data showed, as of 26 June 2022, more than 11 billion doses of vaccine have been administered globally. 2 Previous studies have explored the scope and safety of COVID-19 vaccines, but there is insufficient epidemiological evidence to support the efficacy and safety of vaccinating lactating women because of the absence of clinical...
Many scientific institutions and epidemiologists, based on their previous experience with other vaccines and finite experimental data on COVID-19 vaccines, and fully weighing the benefits and risks of vaccination for lactating women, concluded that the administration of COVID-19 vaccines should be given to all lactating women, and if their conditions put them at greater risk, they should be in the priority group. Given the developmental and health benefits of breast feeding, neither the WHO nor the Academy of Breastfeeding Medicine recommends that mothers should stop breast feeding after receiving the COVID-19 vaccine.

Lactating women might be more hesitant to be vaccinated against COVID-19, a possible hypothesis partly because their bodies have not fully recovered after giving birth and they need to avoid vaccine-related risks, and another because of concerns that the vaccine could threaten the health of newborns or infants through breast milk. An important and easily overlooked point is that some lactating women might experience more severe postpartum anxiety and depressive symptoms during the pandemic, which would also affect their vaccination status. Therefore, the purpose of this study was to investigate the vaccination status of lactating women against COVID-19, analyse the factors affecting their vaccination and provide a reference for healthcare providers to carry out COVID-19 vaccination for lactating women.

**METHODS**

This study promoted a cross-sectional online survey in Changsha City, Hunan Province, China, from September 2021 to December 2021. We divided Changsha into five regions according to the geographical location: east, south, west, north and middle. One community was randomly selected from each region and a total of five communities were selected. A community refers to the social life community composed of people living together in a certain area. The size of the community varies according to the number of nearby buildings and the number of residents within the jurisdiction. Households under jurisdiction range from 1500 to 5000, each of whom belongs to a nearby community. Each community has a community health service centre that provides basic health services to all residents within its jurisdiction. Our research was conducted with the help of community health service centres. Usually, to facilitate the management of health records of all newborns in their districts, WeChat groups have been set up in each community health service centre to inform new parents of their children’s vaccinations and provide them with advice. Considering the inconvenience of lactating women going out during the epidemic, our research was carried out with the help of these WeChat groups. We sent the link of the electronic questionnaire to each lactating woman and carried out several promotions and reminders in the WeChat groups.

**Patient and public involvement**

Patients and the public were not involved in the study design, or in the recruitment to, and conduct of the study.

**Participants**

All participants consisted of women in the community who had given birth and were breast feeding, including those who were exclusively breast feeding, and mixed feeding but not exclusively milk feeding. The required sample size was calculated according to the formula: $n = \frac{\alpha^2 \cdot \hat{p} \cdot (1 - \hat{p})}{\delta^2}$, where $\alpha$ is a 5% margin of error, a 95% CI and a vaccination rate of 65% since some Chinese researchers hold that the vaccination rate of COVID-19 in the population should be 60%–70%. To account for a 10% loss from invalid answers, the theoretical sample size was 422.

**Measures**

The whole questionnaire consists of three parts: general information, knowledge–attitude–behaviour towards COVID-19 and its vaccine, and postpartum psychological status (online supplemental file 2).

**General information**

General information includes age, ethnicity, marital status, education level, place of residence, occupation, medical background, number of children, feeding methods, history of COVID-19 infection, travel history in medium high-risk areas, relationship with family members and physical condition. The questions about medical background, history of COVID-19 infection, and travel history in medium high-risk areas refer to participants and their family members. Medium high-risk areas are classified by the government based on the number of public infections and the severity of the spread of COVID-19, which can be a province, a district or a street.

**Knowledge–attitude–behaviour towards COVID-19 and its vaccine**

Based on China’s Diagnosis and Treatment Protocol for Novel Coronavirus Infected Pneumonia (trial version 5) and related research, we developed a knowledge–attitude–behaviour questionnaire to assess participants’ perceptions and performance of COVID-19 and its vaccines, including the following three dimensions: (1) knowledge—this dimension was assessed by seven items on a 5-point scale (1=very unknown, 5=very familiar), including clinical features, severity, treatment and protection measures for COVID-19, and the type, suitabity, and contraindications of COVID-19 vaccines. (2) Attitude—participants were required to identify 10 items under certain circumstances, such as ‘I think it is necessary for a national COVID-19 vaccination programme’, ‘Vaccination can reduce the likelihood of confirmed patients into intensive care’, ‘I worried that vaccination will be harmful to the baby through breast milk’, etc. Each item was rated from strongly disagree to strongly agree on a scale of 1–5. (3) Behavioural—this dimension involved three items, namely ‘take protective measures in public places’,
‘remind people around to take protective measures’ and ‘persuade family members to get the COVID-19 vaccine’. The answers ranged from very inconsistent (1 point) to very consistent (5 points). The sum of the scores of all items in each subdimension is the score of that dimension, and the total score of the three dimensions is the score of the whole questionnaire. The score was calculated on a scale of 100 points, with higher scores indicating better perceptions and responses to COVID-19.

The content of the questionnaire was determined with the guidance of an epidemiologist, a vaccination manager, and an infectious diseases doctor. The coefficient of variation and Kendall’s harmony coefficient of the three experts’ opinions were 0.116 and 0.483, respectively, and the Cronbach coefficient of the questionnaire was 0.857. Factor analysis was used to evaluate the structural validity; the Kaiser-Meyer-Olkin was 0.795 and Bartlett’s sphericity test reached the significance level (p<0.001), explaining 72.62% of the total variation, which confirmed the satisfactory reliability and validity of this questionnaire. Before the formal distribution of the questionnaire, we conducted a pretest on 10 lactating women. The effective recovery rate and survey quality were guaranteed through settings such as notification, required questions and time limit for answering questions.

Postpartum psychological status
Postpartum psychological status was assessed primarily for anxiety and depressive symptoms, using the seven-item Generalized Anxiety Disorder Scale (GAD-7) and the Edinburgh Postpartum Depression Scale (EPDS), respectively. Both scales use a 4-point scale from 0 to 3, a score of 5 or above in the former indicates anxiety symptoms, while a score of 9 or above in the latter indicates depressive symptoms. The higher the participant’s scores, the more severe their anxiety or depressive symptoms were. Both scales have been widely demonstrated to have appropriate reliability and validity. The internal consistency coefficient of GAD-7 was 0.92, and the test-retest reliability was 0.83. The Cronbach’s alpha for EPDS was 0.87, and the concurrent validity of the EPDS evaluated against the Beck Depression Inventory scores was r=0.79.

Statistical analysis
All analyses were performed using SPSS V.22.0 (SPSS/IBM). Data on demographic information and vaccination status were presented as the means±SD and percentage. χ² and t-tests were used to analyse differences in variables between vaccinated and unvaccinated groups. Logistic regression models were applied to identify factors for vaccination against COVID-19 in lactating women. Bilateral tests were used for all analyses, and a p value of <0.05 was considered statistically significant.

RESULTS
Sample characteristics
A total of 506 lactating women were invited to participate in the study, of whom 457 filled out questionnaires and 432 were included in the final analysis (12=too many missing items, 8=logical error, 5=consistent answer). As shown in table 1, the age of these participants ranged from 20 to 45 years (average 30.9 years), 95.1% of them were Han Chinese and 81.7% were urban residents. Fifty-two (12.0%) had a master’s degree or above, and 95 (22.0%) were housewives. A total of 282 (65.3%) were exclusively breast feeding, and 150 (34.7%) were mixed breast and formula feeding. The duration of breast feeding for these mothers ranged from 1 to 24 months, with an average of 6.9 months. Ten participants (2.3%) reported a history of COVID-19 infection in themselves or family members, and 124 (28.7%) reported a travel history to medium-risk areas. Their score on the COVID-19 knowledge–attitude–behaviour questionnaire was 59.8 (8.8). One hundred twenty-two (28.2%) lactating women reported anxiety symptoms, 93 (21.5%) reported depressive symptoms, and 68 (15.7%) reported both anxiety and depressive symptoms.

Vaccination status
In total, 198 (45.8%) participants received the COVID-19 vaccine, of which 69 (16.0%) reported they were vaccinated entirely voluntarily, 23 (5.3%) at the recommendation of family members and 43 (10.0%) at community advocacy. After vaccination, 49 (11.3%) showed stopping breast feeding and 104 (24.1%) resumed breast feeding after a pause. Of all those vaccinated, 114 (57.6%) said they were willing to get a booster shot if needed, 65 (32.8%) said they were unsure and 19 (9.6%) categorically refused. Among all the reasons why lactating women were not vaccinated against COVID-19, the biggest one is ‘I’m afraid the vaccine will affect the baby through breast milk’ (74.4%), followed by ‘It’s hard to make an appointment or go out so that I have no chance to get vaccinated’ (8.1%). Allergies to vaccine ingredients (3.4%) and worries about vaccine side effects harming their health (3.0%) also account for a certain proportion (table 2).

Comparison of variables between vaccinated and non-vaccinated
The χ² test and t-test were performed to analyse the differences between different participants whether they were vaccinated against COVID-19 or not (0=unvaccinated, 1=vaccinated) as the dependent variable, and the characteristics of the participants as the independent variable. The results showed that there were statistically significant differences in ethnicity, marital status, educational level, medical background, number of children, feeding methods, travel history in medium high-risk areas, physical condition, duration of breast feeding, scores for COVID-19 knowledge–attitude–behaviour, anxiety scores and depressive scores between the two groups (p<0.05). On the contrary, age, place of residence, occupation, history of COVID-19 infection and relationship with family members showed no statistically significant difference between participants (p>0.05) (table 3).
Factors influencing receiving COVID-19 vaccine in lactating women

A binary logistics regression analysis was conducted to investigate the independent factors influencing the vaccination of lactating women against COVID-19. After all the variables with statistical significance in table 3 were included in the model, the result has shown that women with a master’s degree or above (OR=0.03, 95% CI: 0.01 to 0.30), higher anxiety scores (OR=0.66, 95% CI: 0.54 to 0.81) and higher depression scores (OR=0.84, 95% CI:
0.75 to 0.93) were more likely to skip COVID-19 vaccination. Those who were mixed feeding (OR=2.68, 95% CI: 1.82 to 3.96), had longer breastfeeding duration (OR=1.31, 95% CI: 1.16 to 1.49), had a history of high-risk travel (OR=3.49, 95% CI: 1.46 to 8.37), had a better physical condition (OR=5.28, 95% CI: 1.82 to 15.32) and had higher COVID-19 attitude scores (OR=1.18, 95% CI: 1.10 to 1.27) were more likely to receive COVID-19 vaccine. After controlling for age, ethnicity, marital status and place of residence, these factors remained significantly associated with vaccination among lactating women (table 4).

**DISCUSSION**

This study explored the status and related factors of vaccination against COVID-19 among lactating women during the COVID-19 outbreak. We found that only 45.8% of lactating women received the COVID-19 vaccine, lower than the 60%–70% of population vaccination rate expected by Chinese researchers. Among the unvaccinated, 74.4% were concerned that the vaccine might affect the baby’s health through breast milk. This suggests that most lactating women remain sceptical about the safety of vaccines, which is consistent with the findings of Kumari et al. We noticed that 53.5% of women were vaccinated under the advocacy of the unit or the community, which seems encouraging as it might show that the government made efforts to promote COVID-19 vaccination. As we know, almost all COVID-19 vaccinations in China are carried out in the community, which is the government’s primary health service organisation, and the staff regularly remind people to get vaccinated for free. However, as the coronavirus continues to mutate, vaccination could become a long-term adaptation effort, meaning we might need more vaccinations. Therefore, more available data are urgently needed to confirm that COVID-19 vaccines would not threaten the health of infants through breast milk, which might greatly facilitate the acceptance of the COVID-19 vaccine in lactating women.

According to our findings, lactating women with a master’s degree or above were significantly less likely to receive the COVID-19 vaccine than those with junior high school or below education. Women with higher education tend to know better how to get it to their advantage. They might pay more attention to data and documents from governments or authorities, such as literature reports or descriptions with high levels of evidence, before vaccination. Admittedly, no institution could give a positive answer currently because of the absence of lactating women in clinical trials. Another unexpected finding was that 38.3% of lactating women who were not vaccinated against COVID-19 were in a family with a medical background, indicating that some clinical staff hesitated to vaccinate lactating women. A previous study also confirmed that working in healthcare was not associated with vaccine acceptance. Although this factor did not independently predict the vaccination of lactating women, it was a wake-up call for authorities as medical staff play a critical role in influencing vaccination decisions. As pointed out by previous researchers, all individuals facing patients in the clinic should be confident about the safety and effectiveness of COVID-19 vaccines. The current consensus is that the active part of these vaccines is unlikely to reach breast tissue and then the

---

### Table 2 Vaccination status (N=432)

| Variable                                           | Frequency | Prevalence (%) |
|----------------------------------------------------|-----------|----------------|
| Vaccinated or not (N=432)                          |           |                |
| No                                                 | 234       | 54.2           |
| Yes                                                | 198       | 45.8           |
| Willingness to be vaccinated (N=198)                |           |                |
| Completely voluntary                                | 69        | 34.9           |
| Family advice                                      | 23        | 11.6           |
| Work unit advocacy                                 | 63        | 31.8           |
| Community advocacy                                 | 43        | 21.7           |
| Breast feeding after vaccination (N=198)            |           |                |
| Terminate breast feeding                            | 49        | 24.8           |
| Continue breast feeding after a period of pause     | 104       | 52.5           |
| Breast feeding as usual                             | 45        | 22.7           |
| Whether there are adverse reactions after vaccination (N=198) |   |                |
| No or slight adverse reactions                      | 198       | 100.0          |
| Moderate to severe adverse reactions                | 0         | 0              |
| Willingness to get booster shots (N=198)            |           |                |
| Yes                                                | 114       | 57.6           |
| No                                                 | 19        | 9.6            |
| Uncertain                                          | 65        | 32.8           |
| Reasons for not getting vaccinated (N=234)          |           |                |
| I’m worried about the vaccine will affect my health | 7         | 3.0            |
| I’m afraid the vaccine will affect the baby through breast milk | 174 | 74.4 |
| I feel that the prevention and control of the epidemic are sufficient and there is no need to be vaccinated | 15 | 6.4 |
| There are so many types of vaccines that I don’t know which one is better for vaccination | 11 | 4.7 |
| It’s hard to make an appointment or go out so that I have no chance to get vaccinated | 19 | 8.1 |
| I am allergic to a component of the vaccine         | 8         | 3.4            |
Table 3  Comparison of variables between those vaccinated and non-vaccinated (N=432)

| Variable                        | Non-vaccinated (N=234) | Vaccinated (N=198) | $\chi^2$ | P value |
|---------------------------------|-------------------------|--------------------|----------|---------|
| **Classification predictor**    |                         |                    |          |         |
| Ethnicity                       |                         |                    |          |         |
| Han nationality                 | 224 (97.0%)             | 184 (92.9%)        | 3.859    | 0.049   |
| Minority                        | 7 (3.0%)                | 14 (7.1%)          |          |         |
| Marital status                  |                         |                    |          |         |
| Unmarried                       | 14 (6.0%)               | 2 (1.0%)           | 7.436    | 0.006   |
| Married                         | 220 (94.0%)             | 196 (99.0%)        |          |         |
| Education level                 |                         |                    |          |         |
| Junior high school or below     | 26 (11.1%)              | 22 (11.1%)         | 71.349   | <0.001  |
| Senior high school              | 82 (35.0%)              | 41 (20.7%)         |          |         |
| Bachelor’s degree               | 76 (32.5%)              | 133 (67.2%)        |          |         |
| Master’s degree or above        | 50 (21.4%)              | 2 (1.0%)           |          |         |
| Residence                       |                         |                    |          |         |
| Rural                           | 38 (16.2%)              | 41 (20.7%)         | 1.433    | 0.231   |
| Urban                           | 196 (83.8%)             | 157 (79.3%)        |          |         |
| Occupation                      |                         |                    |          |         |
| Farmer                          | 13 (5.6%)               | 10 (5.1%)          | 7.501    | 0.112   |
| Worker                          | 26 (11.1%)              | 23 (11.6%)         |          |         |
| Employee of enterprises/public institutions | 130 (55.6%) | 124 (62.6%) |          |         |
| Student                         | 10 (4.3%)               | 1 (0.5%)           |          |         |
| Housewife                       | 55 (23.5%)              | 40 (20.2%)         |          |         |
| Medical background              |                         |                    |          |         |
| No                              | 196 (83.8%)             | 137 (69.2%)        | 12.886   | <0.001  |
| Yes                             | 38 (16.2%)              | 61 (30.8%)         |          |         |
| Number of children              |                         |                    |          |         |
| 1                               | 124 (53.0%)             | 72 (36.4%)         | 12.064   | 0.002   |
| 2                               | 100 (42.7%)             | 113 (57.1%)        |          |         |
| ≥3                              | 10 (4.3%)               | 13 (6.6%)          |          |         |
| Feeding methods                 |                         |                    |          |         |
| Exclusive breast feeding        | 193 (82.5%)             | 89 (44.9%)         | 66.644   | <0.001  |
| Mixed feeding                   | 41 (17.5%)              | 109 (55.1%)        |          |         |
| History of COVID-19 infection   |                         |                    |          |         |
| No                              | 231 (98.7%)             | 191 (96.5%)        | 2.408    | 0.121   |
| Yes                             | 3 (1.3%)                | 7 (3.5%)           |          |         |
| Travel history in medium high-risk areas | 197 (84.2%) | 111 (56.1%) | 41.462   | <0.001  |
| Yes                             | 37 (15.8%)              | 87 (43.9%)         |          |         |
| Relationship with family        |                         |                    |          |         |
| Poor                            | 10 (4.3%)               | 3 (1.5%)           | 4.383    | 0.112   |
| Average                         | 17 (7.3%)               | 9 (4.5%)           |          |         |
| Good                            | 207 (88.5%)             | 186 (93.9%)        |          |         |
| Physical condition              |                         |                    |          |         |
| Poor                            | 48 (20.5%)              | 15 (7.6%)          | 16.384   | <0.001  |
| Average                         | 116 (49.6%)             | 101 (51.0%)        |          |         |
| Good                            | 70 (29.9%)              | 82 (41.4%)         |          |         |
| **Continuous predictor**        |                         |                    |          |         |
| Age, years                      | 30.5±4.7                | 31.4±4.8           | -1.938   | 0.053   |
| Duration of breast feeding, months | 5.4±2.4                | 8.6±3.4            | -9.562   | <0.001  |
| Score for COVID-19 knowledge–attitude–behaviour | 57.6±7.3 | 62.4±9.7 | -5.716   | <0.001  |
| Knowledge score                 | 20.5±3.0                | 22.4±4.8           | -4.791   | <0.001  |
| Attitude score                  | 27.2±3.3                | 29.3±3.6           | -6.466   | <0.001  |

Continued
infant, and in the unlikely event that it reaches the infant, it is unlikely to have any biological effects.4

In our screening, mixed-feeding women were more likely to receive the COVID-19 vaccine than exclusively breastfeeding women. After vaccination, more than half chose to suspend breast feeding, and 24.8% of them discontinued breast feeding. These moves seemed overly negative, as a prospective cohort study found transient low levels of vaccine mRNA detected in serum from vaccinated mothers occasionally transferred to breast milk, but no evidence could be found to cause sensitisation in infants.22 Previous evidence has shown that none of the COVID-19 vaccines contain live viruses and there is no plausible biological mechanism to explain how a mother’s inactivated vaccine could harm her breastfed baby.8 23 Breast milk has always been considered as a rich source of antibodies for infants. From the perspective of physiology and other previous vaccination experiences, antibodies and T cells, generated by the body and stimulated by vaccines, might passively enter breast milk. Antibodies in breast milk have a strong neutralisation ability, which might bring potential protective effects to nursing infants.24 Two small sample studies had also confirmed that novel coronavirus IgA antibodies were detectable in breast milk 2 weeks after the first injection of the COVID-19 vaccine, IgG antibodies were detectable 3–4 weeks later and antibodies could persist for at least 80 days.25 26 Therefore, while some officials hold that the benefits and risks of vaccination for lactating women should be fully assessed before vaccination, virtually every institution or study, including two evidence-based documents, recommended that breast feeding should not be interrupted or discontinued after the COVID-19 vaccine in lactating women.4 8 27–32

| Table 3 Continued |
|-------------------|
| Variable          | Non-vaccinated (N=234) | Vaccinated (N=198) | \( \chi^2 \) | P value |
|                   | \( n \) | % | \( n \) | % |       |
| Behaviour score   | 9.9±2.7 | 10.7±2.9 | -2.743 | 0.006 |
| Anxiety scores    | 4.6±2.8 | 2.4±1.4 | 10.784 | <0.001 |
| Depression scores | 7.0±3.5 | 4.2±2.8 | 9.495 | <0.001 |

| Table 4 Independent influence of non-vaccination against COVID-19 |
|---------------------|------|------|---------|--------|-----|------|-----|-------|
| Variable             | B    | S_b  | Wald \( \chi^2 \) | P value | OR  | 95% CI | OR* | 95% CI |
| Constant             | -4.184 | 2.009 | 4.336 | 0.037 | 0.02 |      |     |       |
| Education level      |      |      |        |        |     |       |     |       |
| Master’s degree or above | -3.524 | 1.179 | 8.934 | 0.003 | 0.03 | 0.01 to 0.30 | 0.04** | 0.01 to 0.42 |
| Bachelor’s degree    | 0.496 | 0.729 | 0.464 | 0.496 | 1.64 | 0.39 to 6.86 | 3.37 | 0.69 to 16.51 |
| Senior high school   | -0.815 | 0.569 | 2.052 | 0.152 | 0.44 | 0.15 to 1.35 | 0.59 | 0.17 to 2.07 |
| Junior high school or below | 1.00 | 1.00 | 1.00 | 1.00 |
| Feeding methods      |      |      |        |        |     |       |     |       |
| Mixed feeding        | 0.987 | 0.198 | 24.745 | <0.001 | 2.68 | 1.82 to 3.96 | 3.17** | 2.03 to 4.95 |
| Exclusive breast feeding |    |      | 1.00 | 1.00 |     |       |     |       |
| Duration of breast feeding, months | 0.272 | 0.064 | 17.818 | <0.001 | 1.31 | 1.16 to 1.49 | 1.32** | 1.16 to 1.51 |
| Travel history in medium high-risk areas |      |      |        |        |     |       |     |       |
| Yes                 | 1.250 | 0.446 | 7.850 | 0.005 | 3.49 | 1.46 to 8.37 | 3.88** | 1.57 to 9.62 |
| No                  | 1.00 | 1.00 | 1.00 | 1.00 |     |       |     |       |
| Physical condition   |      |      |        |        |     |       |     |       |
| Good                | 1.664 | 0.544 | 9.357 | 0.002 | 5.28 | 1.82 to 15.32 | 4.76** | 1.49 to 15.20 |
| Average             | 1.242 | 0.507 | 6.002 | 0.014 | 3.46 | 1.28 to 9.35 | 2.77 | 0.95 to 8.09 |
| Poor                | 1.00 | 1.00 | 1.00 | 1.00 |     |       |     |       |
| Attitude score for COVID-19 | 0.167 | 0.038 | 19.074 | <0.001 | 1.18 | 1.10 to 1.27 | 1.11* | 1.01 to 1.23 |
| Anxiety scores      | -0.415 | 0.107 | 15.092 | <0.001 | 0.66 | 0.54 to 0.81 | 0.76* | 0.61 to 0.95 |
| Depression scores   | -0.177 | 0.055 | 10.195 | 0.001 | 0.84 | 0.75 to 0.93 | 0.83** | 0.74 to 0.93 |

\*P<0.05; **p<0.01.

*Adjusted for age, ethnicity, marital status and residence.
In this study, we found that lactating women whose family members had travelled to medium high-risk areas were more likely to receive the COVID-19 vaccine than those without risky travel histories. This might be related to the higher self-perceived risk they experienced while travelling. In China, when a place has a large number of new cases or a rapid transmission speed, it will be quickly classified as a medium or high-risk area by the government, and corresponding control measures such as travel restrictions, nucleic acid tests and designated medical treatments will be launched. Once they experienced such strict and effective control measures, people might pay more attention to the epidemic and trust the government more. To cooperate with the authorities, strengthen resistance and make future travels more convenient, vaccination is a wise choice. We also found that lactating women with poorer health showed lower COVID-19 vaccine acceptance, which might be attributable to incomplete recoveries after childbirth, or concern about vaccine side effects, or physical inability to go out.

In the knowledge–attitude–behaviour questionnaire, only the attitude score was significantly associated with vaccination in lactating women. This is similar to previous findings on vaccination intentions among medical students and nurses. Almost everyone had a positive understanding of the transmission characteristics of and protective measures against COVID-19, as well as the role of vaccines, but few had full knowledge of the scope of application and contraindications of vaccines, or even showed a negative attitude. For example, 7.0% of participants agreed with the statement ‘I think healthy people do not need to receive the COVID-19 vaccine’, 36.8% agreed with ‘I am worried about the side effects of the vaccines on my body’ and 87.3% agreed with ‘I am concerned that vaccination will affect the baby’s health through breast milk’. Inappropriate attitudes and motivations are bound to influence the behaviour of participants, so a lack of trust and misinformation might be important reasons for low COVID-19 vaccination rates among lactating women. While awaiting data from phase III clinical trials in other populations and epidemiological data on large numbers of lactating women vaccinated against COVID-19, public health authorities need to make efforts to disseminate correct knowledge to help lactating women shape positive attitudes towards COVID-19 vaccines.

In this study, we found that the prevalence rates of anxiety and depression among lactating women during the pandemic were 28.2% and 21.5%, higher than commonly reported in previous studies for postpartum and lactating women. The main reason might be that previous data reported generalised anxiety during the postpartum period rather than specific anxiety during the epidemic. The precarious situation of the epidemic has further exacerbated maternal anxiety due to insecurity, increased vulnerability to the disease and threat to the health of infants. Maladjustment for new mothers, enforced measures such as social distancing, travel bans and lockdowns might also affect lactating women as they had limited available resources and family support, and hinder routine hospital appointments, which might contribute to increased maternal anxiety and depression. This study confirmed that both anxiety and depression were significantly associated with COVID-19 vaccination in lactating women. We believed that these two might interact, and higher anxiety and depressive symptoms might increase concerns about vaccine safety, and in turn, distrust of vaccines might increase anxiety and depressive symptoms, but further data are needed to confirm this. In a word, public health authorities, biomedical sciences and healthcare researchers should pay more attention to the mental health of lactating women, in addition to the biological and physical effects of COVID-19.

Limitations and future implications
This study has several limitations. First, this is a cross-sectional study and causality could not be inferred. Second, the intentions of lactating women to be vaccinated are time bound and might be influenced by the high prevalence and mortality of the current outbreak. Third, although this study demonstrated that anxiety and depression affected vaccination in lactating women, we did not assess their prenatal or pre-epidemic psychological status, and therefore we could not draw a direct relationship between anxiety, depression and vaccination. Fourth, there were some other possible biases, such as sampling bias due to low response of lactating women with limited internet access, social desirability bias in responses and recall bias in responses.

CONCLUSION
COVID-19 vaccinations among lactating women were associated with physical conditions, education levels, feeding methods, duration of breast feeding, attitudes towards COVID-19, anxiety symptoms and depressive symptoms. Considering that less than 50% of lactating women in this study were vaccinated during the global pandemic, this would pose a huge challenge to post-pandemic vaccine roll-out. Therefore, more evidence is needed to confirm the safety of the vaccine for lactating women, and public health authorities should give lactating women more correct advice and timely interventions based on the factors for the reluctance to vaccinate.

Acknowledgements We would like to acknowledge Kun Tang, Simin Yi and Rong Huang for their assistance as investigators, and Dr Di Wu for manuscript review and feedback.

Contributors XW designed and guaranteed the study, XW, KT, RH and SY analysed the data and interpreted results. XW wrote the initial draft. XW and KT contributed content to subsequent drafts. All authors critically reviewed and approved of the final draft.

Funding This study was supported by the Scientific Research Fund of Hunan Provincial Education Department (21B0079) and Changsha Natural Science Foundation Project (kq202253).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.

Ethics approval This study involves human participants and was approved by the Medical Ethics Committee of Hunan Normal University (Changsha, China; identification code: 20210406, 10 September 2021, online supplemental file 1). All participants provided informed consent as required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Xiaofen Wang http://orcid.org/0000-0002-1911-6201

REFERENCES

1 Organization WH. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021. Available: https://covid19.who.int/ [Accessed 01 Jan 2022].

2 Organization WH. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2022. Available: https://covid19.who.int/ [Accessed 20 Jun 2022].

3 Wu S-C. Progress and concept for COVID-19 vaccine development. Biotechnol J 2020;15:e2000147.

4 Brillo E, Tosto V, Gerli S, et al. COVID-19 vaccination in pregnancy and postpartum. The Journal of Maternal-Fetal & Neonatal Medicine: the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2021;161:1–20.

5 Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69:1653–6.

6 Gynecologists ACoGa: vaccinating pregnant and lactating patients against COVID-19. 2021. Available: https://www.acog.org/en/clinical-clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-COVID-19 [Accessed 01 Jan 2022].

7 India TFeoAGSe: FOGIS position statement COVID vaccination for pregnant and breastfeeding women. 2021. Available: https://www.fogsi.org/COVID-vaccination-for-pregnant-bwomen/ [Accessed 01 Jan 2022].

8 Giampretti A, Eleftheriou G, Gallo M, et al. Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo teratology information service experience during COVID-19 outbreak in Italy. J Perinat Med 2020;48:1001–7.

9 Obstetricians IfoGa: COVID-19 Vaccination for Pregnant and Breastfeeding Women [Internet]. 2021. Available: https://www.ifogo.org/covid-19-vaccination-pregnant-and-breastfeeding-women [Accessed 01 Jan 2022].

10 Organization WH. Coronavirus disease (COVID-19): vaccines safety. 2021. Available: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(COVID-19)-vaccines-safety [Accessed 01 Jan 2022].

11 Public Health England UKG. COVID-19 vaccination: a guide for women of childbearing age, pregnant or breastfeeding [Internet]. 2020. Available: https://www.gov.uk/government/publications/covid-19-vaccination-women-of-childbearing-age-currently-pregnant-planning-a-pregnancy-or-breastfeeding/covid-19-vaccination—a-guide-for-women-of-childbearing-age-currently-pregnant—planning-a-pregnancy—or-breastfeeding [Accessed 01 Jan 2022].

12 Shorey SY, Ng ED, Chee CYI. Anxiety and depressive symptoms of women in the perinatal period during the COVID-19 pandemic: a systematic review and meta-analysis. Scand J Public Health 2021;49:730–40.

13 China CPsGotPrs: Notice on the issuance of COVID-19 Diagnosis and Treatment protocol (Revised version of trial 5th Edition) [Internet]. 2020. Available: http://www.gov.cn/zhengce/zhengceku/2020-02/09/content_5476407.htm [Accessed 20 Jun 2022].

14 Kumar A, Mahery R, Kachhwaha G, et al. Knowledge, attitude, perceptions, and concerns of pregnant and lactating women regarding COVID-19 vaccination: a cross-sectional survey of 313 participants from a tertiary care centre of North India. Diabetes Metab Syndr 2022;16:102449.

15 Toussaint A, Hüsing P, Gurmaz A, et al. Sensitivity to change and minimal clinically important difference of the 7-item generalized anxiety disorder questionnaire (GAD-7). J Affect Disord 2022;265:395–401.

16 Smith-Nielsen J, Matthey S, Lange T, et al. Validation of the Edinburgh postnatal depression scale against both DSM-5 and ICD-10 diagnostic criteria for depression. BMC Psychiatry 2018;18:393.

17 Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2002;166:1092–7.

18 Heh SS. Validation of the Chinese version of the Edinburgh postnatal depression scale: detecting postnatal depression in Taiwanese women. Hu Li Yan Jiu 2001;9:105–13.

19 Wang J, Lyu Y, Zhang H, et al. Willingness to pay and financing preferences for COVID-19 vaccination in China. Vaccine 2021;39:1968–76.

20 Sutton D, D’Alton M, Zhang Y, et al. COVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged women. Am J Obstet Gynecol MFM 2021;3:100403.

21 Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA 2020;323:2459–8.

22 Yeo KT, Shia WN, Tan CW, et al. Neutralizing activity and SARS-CoV-2 vaccine mRNA persistence in serum and Breastmilk after BNT162b2 vaccination in lactating women. Front Immunol 2021;12:783975.

23 National Library of Medicine (US). COVID-19 vaccines. Bethesda, MD: National Library of Medicine (US). 2021. Available: https://www.ncbi.nlm.nih.gov/books/NBK565969/

24 Pace RM, Williams JE, Järvinen KM, et al. COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity. medRxiv 2020:2020.09.16.20196071.

25 Kelly JC, Carter EB, Raghuraman N, et al. Anti-Severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination. Am J Obstet Gynecol 2021;225:101–3.

26 Perl SH, Uzan-Yulzi A, Kliner H, et al. SARS-CoV-2-Specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA 2021;325:2013–4.

27 Davanzo R, Agosti M, Cetlin I, et al. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies. Ital J Pediatr 2021;47:45.

28 India PIBGo: new recommendations of NEVAC accepted by Union Ministry of health, 2021. Available: https://pibgov.in/PressReleasePage.aspx?PRID=1719925 [Accessed 01 Jan 2022].

29 Public Health England UKG. COVID-19: the green book, chapter 14a [Internet]. 2021. Available: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a [Accessed 01 Jan 2022].

30 (CDC) CIDCaP. Information about COVID-19 Vaccines for People Who Are Pregnant or Breastfeeding [Internet]. 2021. Available: https://www.cdc.gov/coronavirus/2019-ncov/covid-data-and-statistics/covid-19-vaccines-for-pregnant-and-breastfeeding-women.html [Accessed 01 Jan 2022].

31 WHO. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know [Internet]. 2021. Available: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know [Accessed 01 Jan 2022].

32 Immunisation JCoVa: Advice on priority groups for COVID-19 vaccination [Internet]. 2020. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950113/jcova-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020-revisedpdf.pdf [Accessed 01 Jan 2022].

33 Liu Q, Liu T, Cui L, et al. Investigation into information release of Chinese government and departments on COVID-19. Data Int Manag 2020;4:220–35.

34 Lucía VC, Kelekar A, Anfoso NM. COVID-19 vaccine hesitancy among medical students. J Public Health 2021;43:445–9.

35 Sirok KO, Li K-K, Wei WI, et al. Editor’s choice: influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey. Int J Nurs Stud 2021;114:103854.
36 Wenzel A, Haugen EN, Jackson LC, et al. Anxiety symptoms and disorders at eight weeks postpartum. *J Anxiety Disord* 2005;19:295–311.
37 Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and health predictors of national postpartum depression prevalence: a systematic review, meta-analysis, and meta-regression of 291 studies from 56 countries. *Front Psychiatry* 2017;8:248.
38 Shorey S, Chee CYI, Ng ED, et al. Prevalence and incidence of postpartum depression among healthy mothers: a systematic review and meta-analysis. *J Psychiatr Res* 2018;104:235–48.
39 Wang Y, Di Y, Ye J, et al. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. *Psychol Health Med* 2021;26:13–22.